Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum
tolerated dose (MTD) and the recommended dose (RD) of PM01183.